Serum Oxidative Stress Markers and Lipidomic Profile to Detect NASH Patients Responsive to an Antioxidant Treatment: A Pilot Study

Table 3

Metabolic data in two groups of NASH patients basal conditions (T0) and after 12 months of treatment with RA (T12).

Parameters	Group 1 T0	Group 1 T12	% variation	𝑃	Group 2 T0	Group 2 T12	% variation	𝑃
BMI	30±1.86	30±1.8	0	ns	28 ± 0.50	26 ± 0.50	9	0.005
Glucose	116±10	105 ± 8.2	−10	0.05	99±2.15	99±2	0	ns
Insulin	18±2.26	17±3.77	−8	ns	23±4.34	14±1.9	−40	0.001
HOMA	5±1	4.5±1.0	−11	ns	5.97±0.6	3.43±0.5	−42	0.001
AST	40±19	27±7	−33	0.05	72±31	41±14	−42	0.01
ALT	40±17	35±10	−14	ns	72±39	50±9	−31	0.05
GGT	67±31	43±12	−35	0.05	101±81	84±75	−16	ns
Steatosis score	1.86±0.90	1.8±0.7	−0.01	ns	1.8±0.8	1.2±0.6	−33	0.01
NAS score	4.67±1.5	3.6±1.15	−29	ns	3.8±1.5	2.5±0.51	−70	0.001
Portal infiltration	1.33±0.8	1.0±0.2	−25	ns	1.2±0.7	0.5±0.3	−58	0.001
Fibrosis	1.35±0.8	0.67±0.5	−50	0.01	1.2±0.7	0.5±0.3	−60	0.001